Reuters logo
BRIEF-Janssen Pharmaceuticals says evidence shows oral invokana 300 mg demonstrates comparable A1C reduction
May 5, 2017 / 11:12 PM / 7 months ago

BRIEF-Janssen Pharmaceuticals says evidence shows oral invokana 300 mg demonstrates comparable A1C reduction

May 5 (Reuters) - Johnson & Johnson

* Janssen Pharmaceuticals - real-world evidence shows oral invokana 300 mg demonstrates comparable A1C reduction and control to injectable GLP-1 receptor agonists

* Janssen Pharmaceuticals Inc - patients on invokana were also less likely to discontinue their medication or be prescribed new antihyperglycemic agent Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below